Francesca Milano

Francesca Milano

Auto-generated profile, based on publicly available information

Francesca Milano

Department of Experimental Internal Medicine, Academic Medical Center, Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2007 in Gastroenterology
Verified
Journal Article
Closed access
FMFrancesca Milano
Francesca Milano
JBJantine W.P.M. van Baal
Jantine W.P.M. van Baal
NBNavtej S. Buttar
Navtej S. Buttar
ARAgnieszka Magdalena Rygiel
Agnieszka Magdalena Rygiel
FKFloor de Kort
Floor de Kort
KKKausilia K. Krishnadath
Kausilia K. Krishnadath

28 May 2015 in Blood
Verified
Journal Article
Open access
PDF file
MMMaria Paola Martelli
Maria Paola Martelli
IGIlaria Gionfriddo
Ilaria Gionfriddo
FMFederica Mezzasoma
Federica Mezzasoma
FMFrancesca Milano
Francesca Milano
SPSara Pierangeli
Sara Pierangeli
‪‪‪Brunangelo ‪Falini
‪Brunangelo ‪Falini
Nucleophosmin (NPM1) mutations represent an attractive therapeutic target in acute myeloid leukemia (AML) because they are common (∼30% AML), stable, and behave as a founder genetic lesion. Oncoprotein targeting can be a successful strategy to treat AML, as proved in acute promyelocytic leukemia by treatment with all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO), which degrade the promyelocytic leukemia (PML)–retinoic acid receptor fusion protein. Adjunct of ATRA to chemotherapy was reported to be beneficial for NPM1-mutated AML patients. Leukemic cells with NPM1 mutation also showed sensibility to ATO in vitro. Here, we explore the mechanisms underlying these observations and show that ATO/ATRA induce proteasome-dependent degradation of NPM1 leukemic protein and apoptosis in NPM1-mutated AML cell lines and primary patients’ cells. We also show that PML intracellular distribution is altered in NPM1-mutated AML cells and reverted by arsenic through oxidative stress induction. Interestingly, similarly to what was described for PML, oxidative stress also mediates ATO-induced degradation of the NPM1 mutant oncoprotein. Strikingly, NPM1 mutant downregulation by ATO/ATRA was shown to potentiate response to the anthracyclin daunorubicin. These findings provide experimental evidence for further exploring ATO/ATRA in preclinical NPM1-mutated AML in vivo models and a rationale for exploiting these compounds in chemotherapeutic regimens in clinics. Key Points ATRA and ATO affect NPM1 protein levels in AML cells and induce cell growth inhibition and apoptosis. AML cells with mutated NPM1 respond to ATRA/ATO, and this might be exploited therapeutically.

1 October 2005 in Gastroenterology
Verified
Journal Article
Closed access
JBJantine W.P.M. van Baal
Jantine W.P.M. van Baal
FMFrancesca Milano
Francesca Milano
ARAgnieszka Magdalena Rygiel
Agnieszka Magdalena Rygiel
JBJacques J.G.H.M. Bergman
Jacques J.G.H.M. Bergman
WRWilda D. Rosmolen
Wilda D. Rosmolen
KKKausilia K. Krishnadath
Kausilia K. Krishnadath

1 May 2014 in Cell Reports
Verified
Journal Article
Open access
LMLuigi Mari
Luigi Mari
FMFrancesca Milano
Francesca Milano
KPKaushal Parikh
Kaushal Parikh
DSDanielle Straub
Danielle Straub
VEVincent Everts
Vincent Everts
KKKausilia K. Krishnadath
Kausilia K. Krishnadath
The molecular mechanisms leading to epithelial metaplasias are poorly understood. Barrett's esophagus is a premalignant metaplastic change of the esophageal epithelium into columnar epithelium, occurring in patients suffering from gastroesophageal reflux disease. Mechanisms behind the development of the intestinal subtype, which is associated with the highest cancer risk, are unclear. In humans, it has been suggested that a nonspecialized columnar metaplasia precedes the development of intestinal metaplasia. Here, we propose that a complex made up of at least two factors needs to be activated simultaneously to drive the expression of intestinal type of genes. Using unique animal models and robust in vitro assays, we show that the nonspecialized columnar metaplasia is a precursor of intestinal metaplasia and that pSMAD/CDX2 interaction is essential for the switch toward an intestinal phenotype.

15 December 2006 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JBJantine W.P.M. van Baal
Jantine W.P.M. van Baal
SDSander H. Diks
Sander H. Diks
RWRonald J.A. Wanders
Ronald J.A. Wanders
ARAgnieszka Magdalena Rygiel
Agnieszka Magdalena Rygiel
FMFrancesca Milano
Francesca Milano
KKKausilia K. Krishnadath
Kausilia K. Krishnadath
The precursor metaplastic mucosal lesion that predisposes for esophageal adenocarcinoma is Barrett's esophagus. Because the signal transduction events that occur in Barrett's esophagus are poorly understood, this study aimed at generating a comprehensive description of cellular kinase activity in Barrett's esophagus, normal squamous esophagus, and gastric cardia to gain more insight into the pathogenesis of Barrett's esophagus. Peptide arrays, exhibiting 1,176 specific consensus sequences for protein kinases, were used to produce a global analysis of cellular kinase activity in biopsies of Barrett's esophagus, and results were compared with the neighboring cardia and squamous epithelia. Several differences in kinase activity using immunoblot analysis and enzyme activity assays were validated in biopsies of 27 Barrett's esophagus patients. Three unique kinome profiles are described and compared. We identified cascades of activated kinases showing that mitogen-activated protein kinase and epidermal growth factor receptor activity are both significantly altered in Barrett's esophagus compared with squamous and gastric cardia epithelia. Another novel finding is that the glycolysis pathway is significantly up-regulated in Barrett's esophagus, which is illustrated by an up-regulated pyruvate kinase activity. Here, the unique kinome profile of Barrett's esophagus is made available as a comprehensive database. Several signaling pathways are revealed as specifically expressed in Barrett's esophagus when compared with the adjacent normal epithelia. These unique findings provide novel insight in the pathogenesis of Barrett's esophagus that will ultimately help to resolve the increasing problem of Barrett's esophagus and prevention of esophageal adenocarcinoma. (Cancer Res 2006; 66(24): 11605-12)

1 January 2013 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
FMFrancesca Milano
Francesca Milano
LMLuigi Mari
Luigi Mari
WLWendy van de Luijtgaarden
Wendy van de Luijtgaarden
KPKaushal Parikh
Kaushal Parikh
SCSilvia Calpe
Silvia Calpe
KKKausilia K. Krishnadath
Kausilia K. Krishnadath
In Western countries the incidence of the esophageal adenocarcinoma (EAC) has risen at a more rapid rate than that of any other malignancy. Despite intensive therapies this cancer is associated with extreme high morbidity and mortality. For this reason, novel effective therapeutic strategies are urgently required. Dendritic Cell (DC)-based immunotherapy is a promising novel treatment strategy, which combined with other anti-cancer strategies has been proven to be beneficial for cancer patients. Curcumin (diferuloylmethane), is a natural polyphenol that is known for its anti-cancer effects however, in it’s free form, curcumin has poor bioavailability. The aim of this study was to investigate whether using a highly absorptive form of curcumin, dispersed with colloidal nano-particles, named Theracurmin would be more effective against EAC cells and to analyze if this new compound affects DC-induced T cell response. As a result, we show efficient uptake of nano-curcumin by the EAC cell lines, OE33, and OE19. Moreover, nano-curcumin significantly decreased the proliferation of the EAC cells, while did not affect the normal esophageal cell line HET-1A. We also found that nano-curcumin significantly up-regulated the expression of the co-stimulatory molecule CD86 in DCs and significantly decreased the secretion of pro-inflammatory cytokines from in vitro activated T cells. When we combined T cells with nano-curcumin treatment in OE19 and OE33, we found that the basic levels of T cell induced cytotoxicity of 6.4 and 4.1%, increased to 15 and 13%, respectively. In conclusion, we found that nano-curcumin is effective against EAC, sensitizes EAC cells to T cell induced cytotoxicity and decreases the pro-inflammatory signals from T cells. Combining DC immunotherapy with nano-curcumin is potentially a promising approach for future treatment of EAC.